Last reviewed · How we verify
QLC5508
QLC5508 is a small molecule drug that targets the molecular target.
QLC5508 is a small molecule drug that targets the molecular target. Used for unknown.
At a glance
| Generic name | QLC5508 |
|---|---|
| Also known as | MHB088C |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | small molecule |
| Target | unknown |
| Modality | Small molecule |
| Therapeutic area | unknown |
| Phase | Phase 3 |
Mechanism of action
QLC5508 works by binding to the molecular target, which leads to a specific therapeutic effect.
Approved indications
- unknown
Common side effects
- unknown
Key clinical trials
- QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (PHASE3)
- A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLC5508 CI brief — competitive landscape report
- QLC5508 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI